Israel’s OncoHost (reported here previously) has achieved about 90% accuracy in predicting how melanoma and lung cancer patients respond to various therapies. And now Israeli Nobel Prize winner Professor Aaron Ciechanover has joined OncoHost’s scientific advisory board. https://www.prnewswire.com/il/news-releases/oncohost-welcomes-nobel-prize-winner-to-scientific-advisory-board-301205142.html https://jitc.bmj.com/content/8/Suppl_3/A11.2 https://www.timesofisrael.com/spotlight/nobel-prizewinner-ciechanover-hails-much-more-precise-cancer-treatment/ … Continue reading →

This video shows that Israeli doctors are saving lives of cancer patients by testing different treatments on samples of the tumors outside of the patient’s body. They can then determine the best cancer treatments to offer patients based on the … Continue reading →

I reported previously (many times) on Israeli companies developing cancer treatments targeting individuals rather than specific areas of the body. Now, Israeli biotech Ayala is partnering with Bristol-Myers Squibb to develop treatments for cancer patients known to have a gene … Continue reading →

Israel’s GeneSort detects specific genetic mutations linked to various types of cancer. Oncologists can then adapt treatments to the patient’s specific genetic mutations, dramatically improving outcomes.  GeneSort has just been acquired by Hong Kong investment fund AID Partners for $23 … Continue reading →

Researchers at Israel’s Bar-Ilan University are the first to analyze biopsies to discover how cancer cells prevent being destroyed by the immune system. As each patient is different, the results will help scientists develop personalized strategies for destroying tumors. https://www.biu.ac.il/en/article/580703 … Continue reading →

Scientists at the Hebrew University of Jerusalem have discovered how DNA methylation acts as a gene control system, like a traffic light that can modulate gene activity and trigger or prevent cancer mutations. It will help develop personalized therapies for … Continue reading →

Normal cells have 23 chromosomes from each parent. But cancer cells do not, and scientists have been trying for years to exploit that fact. Now Tel Aviv University scientists have deciphered the phenomena and can guide oncologists to the therapies … Continue reading →

At its Israeli R&D center, C2i Genomics has developed a personalized, real-time solution for monitoring recurrence and treatment response for various types of solid cancers. It employs a breakthrough tumor DNA pattern recognition approach for liquid biopsy. https://en.globes.co.il/en/article-cancer-recurrence-monitoring-co-c2i-genomics-raises-12m-1001331769 https://c2i-genomics.com/

The Israel Precision Medicine Partnership (IPMP – reported here previously), has granted another NIS 60 million to 16 projects researching into specific targeted personalized medicine that can treat ailments such as autism, cancers and trauma. https://www.timesofisrael.com/16-israeli-research-projects-on-personalized-medicine-get-millions-in-funding/

Israeli scientists are frequently finding new ways of personalizing cancer treatments. Some are based on genetics (see here) or proteins expressed by the body (see here). Now Weizmann Institute researchers are devising a system to predict how patients will respond … Continue reading →